Long-term stability of an aqueous solution containing lidocaine hydrochloride, dexamethasone sodium phosphate and adrenaline hydrochloride for electromotive administration by Vonbach, P et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2009
Long-term stability of an aqueous solution containing lidocaine
hydrochloride, dexamethasone sodium phosphate and adrenaline
hydrochloride for electromotive administration
Vonbach, P; Angelika, H; Dubied, A
Vonbach, P; Angelika, H; Dubied, A (2009). Long-term stability of an aqueous solution containing lidocaine
hydrochloride, dexamethasone sodium phosphate and adrenaline hydrochloride for electromotive administration.
EJHP Science, 15(1):6-10.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
EJHP Science 2009, 15(1):6-10.
Vonbach, P; Angelika, H; Dubied, A (2009). Long-term stability of an aqueous solution containing lidocaine
hydrochloride, dexamethasone sodium phosphate and adrenaline hydrochloride for electromotive administration.
EJHP Science, 15(1):6-10.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
EJHP Science 2009, 15(1):6-10.
EJHP Science • Volume 15 • 2009 • Issue 1 • P. 6-10
© 2009 Pharma Publishing and Media Europe. All rights reserved 1781-7595 25
www.ejhp.eu
6 •  • Volume 15 • 2009/1 • www.ejhp.eu 
For personal use only. Not to be reproduced without permission of the publisher (copyright@ppme.eu).
INTRODUCTION
Electromotive drug administration (EMDA), which is also 
known as iontophoresis, involves the active transport 
of ionised drugs into the deeper bladder layers by the 
application of an electric current.
Long-term stability of an aqueous solution containing 
lidocaine hydrochloride, dexamethasone sodium phos-
phate and adrenaline hydrochloride for electromotive 
administration
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ABSTRACT
Study objectives: In the Urology Department of the State Hospital of Baden, females with non-infectious chronic cystitis 
are treated with electromotive drug administration of lidocaine hydrochloride (20 mg/mL), dexamethasone sodium phos-
phate (0.2 mg/mL) and adrenaline hydrochloride (0.01 mg/mL). The aim of this study was to investigate the long-term 
stability of the solution administered.
Methods: The solution investigated was stored at three different temperatures (-20°C, 4°C and 20°C). Concentrations 
were measured by high-performance liquid chromatography (HPLC) on day 0 (baseline), 7, 14, 21, 28 and after two, 
three and six months. Lidocaine was analysed according to the chromatographic system described in the United States 
Pharmacopeia (USP) [1]. The analysis of dexamethasone was performed by the same chromatographic system as for 
lidocaine. Adrenaline was analysed separately, also according to the USP, but with a modified mobile phase.
Validation of the methods was performed regarding the reproducibility, the linearity and the selectivity.
Results: Lidocaine was stable during the study period of six months at all three temperature conditions (98%-99%). 
The degradation of dexamethasone did not exceed 5%; the content after six months was 98% at both -20°C and 4°C, 
and 95% at 20°C. The concentration of adrenaline was constant at -20°C; at 4°C it was stable for three months (100%, 
expressed as a percentage of the initial dose) and declined to 94% after six months.
Conclusion: The aqueous solution of lidocaine, dexamethasone and adrenaline is stable for six months at -20°C and for 
three months at 4°C.
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The treatment of female patients suffering from non-
infectious chronic cystitis (NICC) with EMDA of lidocaine 
and dexamethasone, followed by hydrodistension of the 
bladder is reported to be convenient and well tolerated 
[2-4]. Other studies have shown the effectiveness of 
lidocaine with adrenaline [5], and of either lidocaine 
[6] or dexamethasone [7] as the sole active agent. 
Intravesical EMDA in NICC patients is effective and safe. 
The therapeutic concept combines the advantages of 
increased drug administration without systemic side 
effects [2-7].
In the Urology Department of the State Hospital of 
Baden, females with NICC are treated with EMDA of 
lidocaine, dexamethasone and adrenaline. Limited infor-
mation is available about the long-term stability and 
compatibility of these three compounds. Therefore, the 
solution needs to be mixed just before administration 
and under aseptic conditions by the pharmacy staff. 
Large scale preparation helps to optimise deployment 
of personnel and minimise time spent on vial production; 
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the stability of the solution allows enhancement of the 
supply inventory.
The aim of this study was to investigate the long-term 
stability of lidocaine hydrochloride (20 mg/mL), dexa-
methasone sodium phosphate (0.2 mg/mL) and adrena-
line hydrochloride (0.01 mg/mL), in aqueous solution at 
three different temperatures.
MATERIALS AND METHODS
Solution preparation and storage
The solution to be investigated was prepared with lidocaine 
hydrochloride (PhEur, Hänseler AG, Herisau, Switzerland, 
batch number: 2004.06.0792, expiry date: 08/2008), 
dexamethasone sodium phosphate (Mephameson injec-
tion solution 50 mg/3 mL, Mepha Pharma AG, Aesch, 
Switzerland, batch number: 0370006, expiry date: 
02/2006) and adrenaline hydrochloride (Adrenalin Sintet-
ica injection solution 1 mg/mL, Sintetica SA, Mendrisio, 
Switzerland, batch number: 04070, expiry date: 04/2006). 
The solution was divided between 32 brown glass 20 mL 
vials and eight white glass 20 mL vials; all the vials were of 
type II glass quality. Eight brown glass vials were stored at 
three different temperatures (-20°C, 4°C and 20°C) each. 
In addition, the solution was exposed to stress conditions 
(eight brown glass vials at 40°C and eight white glass vials 
at daylight and 20°C).
Standard solutions
The standard solutions were prepared with working 
standards: lidocaine hydrochloride (PhEur, Hänseler AG, 
Herisau, Switzerland), dexamethasone sodium phosphate 
(Ciba Vision Ltd, Hettlingen, Switzerland, batch number: 
0846299, expiry date: no expiry data available) and both the 
laevo- and dextro-enantiomers of adrenaline hydrochloride 
(Sigma-Aldrich Chemie GmbH, Buchs, Switzerland, batch 
number: 123K1187, expiry date: 04/2006). The concen-
trations of these working standards were specified by the 
corresponding reference substances (Chemical Refer-
ence Standard, European Directorate for the Quality of 
Medicines & HealthCare, Strasbourg, France; lidocaine 
hydrochloride: batch number 1; dexamethasone sodium 
phosphate: batch number: 3; adrenaline: batch number: 1; 
no expiry dates available). In the following text, the three 
drugs under investigation will be referred to as lidocaine, 
dexamethasone and adrenaline.
Analytical methods and chromatographic conditions
The lidocaine content was determined according to the 
chromatographic system described in the USP [1]. The 
analysis of dexamethasone was performed with the same 
chromatographic system as for lidocaine, in the same 
chromatogram. Although this is not the USP method 
for the determination of dexamethasone, the validation 
showed that the same system could be used for both 
drugs.
The eluent used in the analysis of lidocaine and dexa-
methasone was prepared with four volumes of meth-
anol to six volumes of an aqueous solution—the 
sodium salt of 1-octane sulphonic acid at ten times the 
usual concentration, the disodium salt of ethylenedi-
amine-tetraacetic acid dehydrate, sodium dihydrogen 
phosphate, ortho-phosphoric acid, 85% and freshly 
demineralised water.
Adrenaline was analysed separately, according to the 
chromatographic system described in the USP [1], but 
with a modified eluent that was prepared with one volume 
acetonitrile to four volumes of an aqueous solution (glacial 
acetic acid, sodium hydroxide 1 mol/L and demineralised 
water) with a pH of 3.4.
The chromatographic apparatus and the conditions 
of the HPLC methods were as follows: the HPLC sys-
tem (Metrohm 2250, Metrohm AG, Herisau, Switzer-
land) was used with a pump (model Z 1010, Bischoff 
GmbH) and an ultra violet/visible (UV-VIS) detector 
(Lambda 1010, Bischoff GmbH) and a data acquisition 
and processing module (Metrohm IC Net, version 2.3, 
Metrohm AG). Symmetry columns were C8 (adrenaline) 
and C18 (lidocaine hydrochloride and dexamethasone 
sodium phosphate), both, size 4.6 × 250 mm and par-
ticle size 5.0 µm (Waters Associates, Baden-Dättwil, 
Switzerland).
For lidocaine and dexamethasone, the flow rate was 1.5 mL 
per minute, with a column temperature of 25°C ± 1.0°C 
and ultraviolet detection at 254 nm. For adrenaline, the 
flow rate was 1.0 mL per minute, with a column at room 
temperature and ultraviolet detection at 280 nm. The cal-
culation of the area under the curve was carried out auto-
matically by intrapolation (Metrohm IC Net, version 2.3, 
Metrohm AG).
Validation of the analytical methods
Validation of the methods was performed regarding repro-
ducibility, linearity and selectivity. Furthermore, the stability-
indicating ability of the test was examined.
Reproducibility 
The within-day relative standard deviation was determined 
by measuring each drug eight times at the concentrations 
investigated. Each measurement was performed in the 
presence of all three compounds.
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Linearity 
Linearity was evaluated by serial dilutions with demineralised 
water to 50%, 80%, 100%, 120% and 150% relative to 
the concentrations investigated. Each measurement was 
performed in the presence of all three compounds. The 
correlation coefficients were calculated by linear regression 
analysis of the peak area.
Selectivity 
The selectivity of each compound was tested in the presence 
of the other agents including the adjuvant substances in 
Mephameson injection solution (sodium chloride, propylene 
glycol and ethylenediamine-tetraacetic acid disodium salt dehy-
drate). The adjuvant substances were added to the standard 
solutions resulting in the following concentrations: 0.01 mg/mL 
sodium chloride, 1.2 µl/mL propylene glycol and 0.01 mg/mL 
ethylenediamine-tetraacetic acid disodium salt dihydrate. In 
order to test the assay as a concomitant indicator of the stabil-
ity of the drugs, they were stressed at 40°C for six months.
Stability study
Concentrations were measured by HPLC on day 0 (base-
line), 7, 14, 21, 28 and after two, three and six months. 
Solutions were measured under stress conditions only 
during the first month. Each solution was prepared and 
measured twice. Data were expressed as mean values of 
the percentage of the initial dose.
RESULTS AND DISCUSSION
Validation of the analytical methods
The results of the validation are shown in Table 1. Figure 1 
shows the chromatogram of adrenaline hydrochloride and 
its decomposition products after 28 days at 40°C.
Stability study
The retention time for lidocaine hydrochloride was four min-
utes and the area under the curve (AUC) ~2,200 mV × sec; 
dexamethasone showed a retention time of 22 minutes 
(AUC ~300 mV × sec). The retention time for adrenaline 
was approximately seven minutes, the AUC of the initial 
dose was represented by about 88 mV × sec (Figure 2).
Lidocaine was stable for the whole study period of six 
months under all three conditions (98-99%), even under 
stress conditions (97-98% after six months). Aqueous solu-
tions of lidocaine are reported to be stable to heat, acids 
Figure 1:  Chromatogram of adrenaline hydrochloride 
and decomposition products at 280 nm after 
stress testing at 40°C for 28 days
Adrenaline hydrochloride peak: retention time 6.99 minutes, area under 
the curve 47 mV × sec
Table 1:  Results of the validation of the analytical methods: reproducibility (within-day, n = 8), linearity and selectivity
Lidocaine hydrochloride Dexamethasone sodium 
phosphate
Adrenaline hydrochloride
Reproducibility (area 
under the curve, standard 
deviation, relative 
standard deviation)
2,216.15 ± 7.02 (0.3%) 280.60 ± 6.50 (2.3%) 83.05 ± 0.62 (0.8%)
Linearity (correlation 
coefficient, r2)
0.9988 0.9996 0.9996
Selectivity The peak areas of the agents alone and together with the added substances, respectively, were 
identical for all three agents. No visible peaks at the corresponding retention times of the three drugs 
were detected on eluting the adjuvant substances alone.
Stability-indicating test 
(at 40°C) (percentage of 
integer substance)
After six months: 97.6%; no visible 
decomposition products in the 
chromatogram at 254 nm 
After six months: 58.0%; no visible 
decomposition products in the 
chromatogram at 254 nm
After 28 days: 28.7%; 
chromatogram showing 
decomposition products at 
280 nm (Figure 1)
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Figure 2:  Chromatogram of a) adrenaline hydrochloride, 
lidocaine hydrochloride and dexamethasone 
sodium phosphate at 280 nm and b) adrenaline 
hydrochloride alone at 280 nm
a)
b)
Adrenaline hydrochloride peak: retention time 7.12 minutes, area under 
the curve 88 mV × sec
and 56% after six months) and under stress conditions 
(daylight or 40°C). It is possible that gassing of the vials 
with nitrogen would have resulted in a longer duration of 
stability, because adrenaline is sensitive to light and air 
[8]. The pH of the investigated solution was 5.7. Adjust-
ment to the optimum pH for adrenaline (3-4) [8] could 
induce even longer stability.
and alkalis. Furthermore, the compatibility of lidocaine 
2 mg/mL and dexamethasone 4 µg/mL was already 
proven. However, the time period of the stability analysis 
was not stated by Trissel [8].
The degradation of dexamethasone did not exceed more 
than 5%. The concentration after six months was 98%, 
both at -20°C and 4°C and 95% at 20°C (Figure 3). 
According to Trissel [8], the concentrated solutions 
(4 mg/mL and 24 mg/mL) should be protected from light 
and from freezing. Diluted solutions (0.2 mg/mL) were 
found to be stable at 4°C for 30 days followed by two 
days at 23°C [8].
The concentration of adrenaline was constant at -20°C 
(Figure 4). At 4°C it was stable for three months (100%, 
expressed as a percentage of the initial content) and 
declined to 94% after six months. Faster degradation 
occurred at 20°C (98% after 21 days, 90% after 28 days 
Figure 3:  Stability of dexamethasone sodium phosphate 
at 0.2 mg/mL in aqueous solution with 
adrenaline hydrochloride (0.01 mg/mL) and 
lidocaine hydrochloride (20 mg/mL)
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Figure 4:  Stability of adrenaline hydrochloride at 
0.01 mg/mL in aqueous solution with lidocaine 
hydrochloride (20 mg/mL) and dexamethasone 
sodium phosphate (0.2 mg/mL)
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Limitation
Because each solution was prepared and measured twice, 
we were able to calculate means, but without confidence 
intervals.
CONCLUSION
The aqueous solution of lidocaine hydrochloride (20 mg/
mL), dexamethasone sodium phosphate (0.2 mg/mL) and 
adrenaline hydrochloride (0.01 mg/mL) is stable for six 
months at -20°C and for three months at 4°C.
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